DC
CBAY

Diametric Capital’s Cymabay Therapeutics CBAY Stock Holding History

Diametric Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33,706
Closed -$294K – 495
2023
Q1 		$294K Buy
+33,706
New +$270K 0.14% 197

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Diametric Capital's CBAY Position: Q2 2023 in Review

Diametric Capital sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 33,706 shares — an estimated $294K sold.

Diametric Capital first reported a position in CBAY in Q1 2023 and held it in 1 quarter. The position peaked at $294K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • Diametric Capital reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Diametric Capital sold 33,706 Cymabay Therapeutics shares in Q2 2023, an estimated $294K.
  • Diametric Capital first reported a position in Cymabay Therapeutics in Q1 2023 and held it in 1 quarter.
  • Diametric Capital's Cymabay Therapeutics position peaked at $294K in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.